DEL Webinar
About the Live Webinar
| Title: | “Rethinking Medicinal Chemistry: Revolutionizing Lead Generation with Cutting-Edge On-DNA Chemistry” |
| Date | Time | Duration: | 10th December 2024 | 4 pm CEST | 7am PST | 10am EDT | 30 minutes |
| Speakers | Dr. Thorsten Genski (Serengen), Dr. Anil Argarwal (Taros Chemicals) |
Join the upcoming live webinar titled “Rethinking Medicinal Chemistry: Revolutionizing Lead Generation with Cutting-Edge On-DNA Chemistry” on December 10th at 4 PM CET. In this 30-minute session, discover how innovative On-DNA Chemistry is transforming drug discovery by accelerating processes, amplifying insights, and reducing costs.
Key learnings from this webinar include:
- The advantages of DNA-Encoded Library (DEL) drug discovery, offering unparalleled efficiency in identifying lead compounds.
- Insight into the challenges of traditional DEL synthesis and how modern approaches overcome these hurdles.
- An overview of the key components and benefits of novel DEL strategies, enabling more precise and effective drug discovery.
- How to harness the power of chemistry in DEL design for optimal results.
- Strategies for addressing drug discovery-relevant spaces using DELs to expand the possibilities of medicinal chemistry.
Speaker 1) Dr.Thorsten Genski, CEO Serengen GmbH
Thorsten Genski is the CEO of Serengen GmbH, where he leads efforts to innovate drug discovery using advanced DNA-encoded library (DEL) technology in combination with artificial intelligence. Before taking on this role, Genski built an extensive background in the life sciences and biotech sectors, having held key positions that honed his expertise in scientific research, technology development, and business leadership. He previously worked with companies specializing in biotechnology solutions, where he gained valuable experience in project management and innovation within the pharmaceutical and biotechnology industries. His career trajectory reflects a deep commitment to leveraging new technologies to accelerate the development of therapeutic solutions, with a particular focus on enhancing the precision and efficiency of drug discovery processes. At Serengen, Genski continues to push the boundaries of drug discovery by fostering strategic partnerships and driving the company’s mission to make serendipitous scientific breakthroughs more systematic and accessible.
Speaker 2) Dr. Anil Argarwal – Head of Medicinal Chemistry
Anil is a distinguished medicinal chemist with over 17 years of experience specializing in early drug discovery across various
therapeutic areas including Oncology, Neuroscience, anti-infectives, and metabolic diseases.
A PhD graduate from the University of Leeds, Anil has contributed
significantly to the field, notably as a coinventor of two clinical-stage molecules:
ALK5i – PF 06952229 (Pfizer) and CDK 2,4,6 inhibitor – NUV-422 (Nuvation Bio), both currently in Phase-I trials.
His recent work includes leading over ten drug discovery projects, advancing two clinical candidates, and numerous lead molecules in areas such as oncology and liver disease.
Notably, a molecular glue has been nominated for further development with Anil credited as an inventor. His expertise extends to optimizing lead molecules through structure-activity relationship analysis, greatly enhancing project outcomes and organizational growth.
Any questions before our webinar?
contact us in advance to arrange a personal meeting
Drug Discovery
Custom Synthesis
We support our customers by providing first kg quantities of fine and specialty chemicals, cost reduction of existing syntheses, streamlining chemical processes considering…
